{"id":"NCT01214720","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer","officialTitle":"A Randomized, Double-blind Study of the Effect of Avastin Plus Gemcitabine and Erlotinib Compared With Placebo Plus Gemcitabine and Erlotinib on Overall Survival in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-07","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2010-10-05","resultsPosted":"2014-08-13","lastUpdate":"2014-08-13"},"enrollment":607,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pancreatic Cancer"],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"}],"summary":"This study will evaluate efficacy, safety and tolerability of Avastin versus placebo added to a chemotherapeutic regimen in patients with metastatic pancreatic cancer. The anticipated time of study treatment is until confirmed evidence of disease progression, and the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Duration of Overall Survival - Percentage of Participants With an Event","timeFrame":"Randomization, Weeks 1-8 of Cycle 1, Weeks 1-3 of consecutive cycles, 28 days and 3 months after lst treatment, and every 3 months for up to 18 months from last participant randomized","effectByArm":[{"arm":"Bevacizumab + Gemcitabine + Erlotinib","deltaMin":72.2,"sd":null},{"arm":"Placebo + Gemcitabine + Erlotinib","deltaMin":77.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":101,"countries":["Australia","Austria","Belgium","Canada","China","Czechia","Finland","France","Germany","Israel","Italy","Netherlands","New Zealand","Peru","Poland","Singapore","South Africa","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":139,"n":297},"commonTop":["Diarrhoea","Nausea","Rash","Vomiting","Fatigue"]}}